Table 2.
Baseline parameters on efficacy measures (mITT population).
| Baseline Parameters, mean (SD) | Placebo (n = 214) | Atogepant 10 mg QD (n = 214) | Atogepant 30 mg QD (n = 223) | Atogepant 60 mg QD (n = 222) |
|---|---|---|---|---|
| Monthly migraine days | 7.5 (2.4) | 7.5 (2.5) | 7.9 (2.3) | 7.8 (2.3) |
| Monthly headache days | 8.4 (2.6) | 8.4 (2.8) | 8.8 (2.6) | 9.0 (2.6) |
| Monthly cumulative headache hours | 51.1 (34.5) | 47.4 (27.3) | 49.5 (26.7) | 50.4 (27.4) |
| Monthly acute medication use days | 6.5 (3.2) | 6.6 (3.0) | 6.7 (3.0) | 6.9 (3.2) |
| Monthly moderate/severe headache days | 6.5 (2.6) | 6.4 (2.6) | 6.9 (2.5) | 6.9 (2.6) |
| Weekly migraine days* | 1.9 (0.6) | 1.9 (0.6) | 2.0 (0.6) | 1.9 (0.6) |
mITT, modified intent-to-treat; QD, once daily; SD, standard deviation.
*For weekly data, baseline was defined as monthly migraine days divided by 4, and change from baseline in weekly migraine days was to be calculated for consecutive 7-day periods beginning with day 1.